Abstract
Purpose. Amphotericin B in small, unilamellar liposomes (AmBisome) is safer and produces higher plasma concentrations than other formulations. Because liposomes may increase and prolong tissue exposures, the potential for drug accumulation or delayed toxicity after chronic AmBisome was investigated.
Methods. Rats (174/sex) received intravenous AmBisome (1, 4, or 12 mg/kg), dextrose, or empty liposomes for 91 days with a 30-day recovery. Safety (including clinical and microscopic pathology) and toxicokinetics in plasma and tissues were evaluated.
Results. Chemical and histopathologic changes demonstrated that the kidneys and liver were the target organs for chronic AmBisome toxicity. Nephrotoxicity was moderate (urean nitrogen [BUN] ≤51 mg/dl; creatinine unchanged). Liposome-related changes (vacuolated macrophages and hypercholesterolemia) were also observed. Although plasma and tissue accumulation was nonlinear and progressive (clearance and volume decreased, half-life increased with dose and time), most toxic changes occurred early, stabilized by the end of dosing, and reversed during recovery. There were no delayed toxicities. Concentrations in liver and spleen greatly exceeded those in plasma; kidney and lung concentrations were similar to those in plasma. Elimination half-lives were 1-4 weeks in all tissues.
Conclusions. Despite nonlinear accumulation, AmBisome revealed predictable hepatic and renal toxicities after 91 days, with no new or delayed effects after prolonged treatment at high doses that resulted in plasma levels >200 μg/ml and tissue levels >3000 μg/g.
Similar content being viewed by others
REFERENCES
I. Bekersky, R. M. Fielding, D. Buell, and I. Lawrence. Lipidbased amphotericin B formulations: from animals to man. Pharm. Sci. Technol. Today 2:230–236 (1999).
R. M. Fielding, A. W. Singer, L. H. Wang, S. Babbar, and L. S. S. Guo. Relationship of pharmacokinetics and tissue distribution to reduced toxicity of colloidal amphotericin B in dogs. Antimicrob. Agents Chemother. 36:299–307 (1992).
K. M. Wasan, A. L. Kennedy, S. M. Cassidy, et al. Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies. Antimicrob. Agents Chemother. 42:3146–3152 (1998).
J. P. Sculier, A. Coune, F. Meunier. Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections. Eur. J. Cancer Clin. Oncol. 24:527–538 (1988).
G. Lopez-Berestein, V. Fainstein, R. Hopfer, et al. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: A preliminary study. J. Infect. Dis. 151:704–710 (1985).
R. P. Rapp, P. O. Gubbins, and M. E. Evans. Amphotericin B lipid complex. Ann. Pharmacother. 31:1174–86 (1997).
R. T. Proffitt, A. Satorius, S.-M. Chiang. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J. Antimicrob. Chemother. 28(suppl. B):49–61 (1991).
K. V. Clemons and D. A. Stevens. Therapeutic efficacy of a liposomal formulation of amphotericin B (AmBisome) against murine blastomycosis. J. Antimicrob. Chemother. 32:465–472 (1993).
T. J. Walsh, V. Yeldandi, M. McEvoy. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob. Agents Chemother. 42:2391–2398 (1998).
T. J. Walsh, R. W. Finberg, C. Arndt. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. New Engl. J. Med. 340:764 (1999).
J. R. Wingard, M. H. White, E. J. Anaissie. A randomized double-blind safety study of AmBisome and Abelcet in febrile neutropenic patients. 9th Focus on Fungal Infections Meeting, March 1999, San Diego, CA, Abstr. 15.
I. Bekersky, D. Buell, M. Tomishima, K. Maki, I. Lawrence, and R. M. Fielding. New approaches to systemic antifungal therapy: Case studies of AmBisome and FK463. Recent Res. Devel. Antimicrob. Agents Chemother. 3:407–413 (1999).
A. J. Coukell and R. N. Brogden. Liposomal amphotericin B: Therapeutic use in the management of fungal infections and visceral leishmaniasis. Drugs 55:585–612 (1998).
G. W. Boswell, D. Buell, and I. Bekersky. AmBisome (liposomal amphotericin B): a comparative review. J. Clin. Pharmacol. 38: 583–592 (1998).
T. J. Walsh, E. J. Anaissie, J. L. Goodman. High-dose liposomal amphotericin B in patients infected with aspergillosis and other filamentous fungi. In Abstracts 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society of Microbiology, Washington, DC, 1999, p. 573.
G. W. Boswell, I. Bekersky, D. Buell, R. Hiles, and T. J. Walsh. Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats. Antimicrob. Agents Chemother. 42:263–268 (1998).
I. Bekersky, G. W. Boswell, R. Hiles, R. M. Fielding, D. Buell, and T. J. Walsh. Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome) in Beagle dogs. Pharm. Res. 16:1694–1701(1999).
R. M. Fielding, R. O. Lewis, and L. Moon-McDermott. Altered tissue distribution and elimination of amikacin encapsulated in unilamellar, low-clearance liposomes (MiKasome®). Pharm. Res., 15:1775–1781 (1998).
A. Alak, S. Moys, and I. Bekersky. A high-performance liquid chromatographic assay for the determination of amphotericin B serum concentrations after the administration of AmBisome, a liposomal amphotericin B formulation. Ther. Drug Monit. 18: 604–609 (1996).
A. C. Parekh, R. J. Creno, and C. V. Dave. Hypercholesterolemic effect of amphotericin B: an analytical approach. Res. Commun. Chem. Pathol. Pharmacol. 9:307–314 (1974).
A. D. Dayan and P. K. Working. Non-clinical studies of the efficacy, pharmacokinetics and safety of amphotericin B colloidal dispersion (ABCD). Round Table Ser. R. Soc. Med. Press 32:12–26 (1994).
P. Longuet, V. Joly, P. Amirault, N. Seta, C. Carbon, and P. Yeni. Limited protection by small unilamellar liposomes against the renal tubular toxicity induced by repeated amphotericin B infusions in rats. Antimicrob. Agents Chemother. 35:1303–1308 (1991).
P. K. Working, M. S. Newman, T. Sullivan, M. Brunner, M. Podell, Z. Sahenk, and N. Turner. Comparative intravenous toxicity of cisplatin solution and cisplatin encapsulated in longcirculating, pegylated liposomes in cynomolgus monkeys. Toxicol. Sci. 46:155–165 (1998).
R. M. Fielding, G. Mukwaya, and R. A. Sandhaus. Clinical and preclinical studies with low-clearance liposomal Amikacin (Mi-Kasome). In M. C. Woodle and G. Storm (eds.), Long-Circulating Liposomes: Old Drugs, New Therapeutics, Springer-Verlag, Berlin, 1998, pp. 213–225.
J. P. Tolins and L. Raij. Chronic amphotericin B nephrotoxocity in the rat: Protective effect of calcium channel blockade. J. Am. Soc. Nephrol. 2:98–102 (1991).
L. H. Wang, R. M. Fielding, P. C. Smith, and L. S. S. Guo. Comparative tissue distribution and elimination of amphotericin B colloidal dispersion (Amphocil) and Fungizone after repeated dosing in rats. Pharm. Res. 12:275–283 (1995).
H.-H. Chow, Y. Cai, and M. Mayersohn. Disposition kinetics of amphotericin B in rats, the influence of dose. Drug Metab. Disp. 20:432–435 (1992).
R. M. Fielding, P. C. Smith, L. H. Wang, J. Porter, and L. S. S. Guo. Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob. Agents Chemother. 35:1208–1213 (1991).
H. Ellens, E. Mayhew, and Y. M. Rustum. Reversible depression of the reticuloendothelial system by liposomes. Biochim. Biophys. Acta 714:479–485 (1982).
H. Harashima and H. Kiwada. Liposomal targeting and drug delivery: kinetic consideration. Adv. Drug Deliv. Rev. 19:425–444 (1996).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bekersky, I., Boswell, G.W., Hiles, R. et al. Safety, Toxicokinetics and Tissue Distribution of Long-Term Intravenous Liposomal Amphotericin B (ambisome®): A 91-day Study in Rats. Pharm Res 17, 1494–1502 (2000). https://doi.org/10.1023/A:1007605024942
Issue Date:
DOI: https://doi.org/10.1023/A:1007605024942